Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01517451 · ClinicalTrials.gov registry record · Phase 1
Radiation and Androgen Ablation for Prostate Cancer
A Phase 1 study of Adenocarcinoma of the Prostate, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 3
- Study locations
NCT01517451 is a Phase 1 study of Adenocarcinoma of the Prostate that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 45 participants, below the 107-participant average among 21 other Adenocarcinoma of the Prostate trials with a reported enrollment target (58% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT01517451, a Phase 1 study of Adenocarcinoma of the Prostate, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 3
- Study locations
Study Summary
A study to see how effective and tolerable radiation therapy along with androgen deprivation therapy is in treating prostate cancer.
Conditions Studied
Interventions
- RADIATION Radiation Therapy
- DRUG Androgen Deprivation Therapy (ADT)
Study Locations (3)
Maryland
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
- Suburban Hospital - Bethesda
District of Columbia
- Sibley Memorial Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2013-05-22 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01517451
The ClinicalTrials.gov registry entry for NCT01517451 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 107-participant average among 21 other Adenocarcinoma of the Prostate trials with a reported enrollment target (58% lower). The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Adenocarcinoma of the Prostate appearing as the primary indexed condition, and to 2 interventions - of which Radiation Therapy is the first listed.
NCT01517451 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Maryland, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT01517451 about?
NCT01517451 is a clinical study titled "Radiation and Androgen Ablation for Prostate Cancer". A study to see how effective and tolerable radiation therapy along with androgen deprivation therapy is in treating prostate cancer.
What is the current status of trial NCT01517451?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2013-05-22. Estimated completion is 2025-12-31.
What conditions does trial NCT01517451 study?
This clinical trial studies the following conditions: Adenocarcinoma of the Prostate.
What interventions are being tested in trial NCT01517451?
The interventions under investigation include: Radiation Therapy (RADIATION), Androgen Deprivation Therapy (ADT) (DRUG).
Who is sponsoring clinical trial NCT01517451?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01517451 being conducted?
This trial has 3 study locations across District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenocarcinoma of the Prostate
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)
ACTIVE NOT RECRUITING · Phase 1
-
High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer
COMPLETED · Phase 1
-
Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy
COMPLETED · Phase 1
-
Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.